Efficacy and safety of onabotulinumtoxinA with standardized physiotherapy for the treatment of pediatric lower limb spasticity: A randomized, placebo-controlled, phase III clinical trial

Rozalina Dimitrova, Heakyung Kim, Jill Meilahn, Henry G. Chambers, Brad A. Racette, Marcin Bonikowski, Eun Sook Park, Emily McCusker, Chengcheng Liu, Mitchell F. Brin

Research output: Contribution to journalArticlepeer-review

1 Scopus citations

Abstract

BACKGROUND: Spasticity is common in cerebral palsy and can result in pain and diminished health-related quality of life. OBJECTIVE: To evaluate the safety and efficacy of onabotulinumtoxinA for lower limb spasticity treatment in children with cerebral palsy. METHODS: In this registrational phase 3, multinational, randomized, double-blind, placebo-controlled trial (NCT01603628), children (2-<17 years) with cerebral palsy and ankle spasticity (Modified Ashworth Scale-Bohannon [MAS] score≥2) were randomized 1:1:1 to standardized physical therapy and onabotulinumtoxinA (4 or 8U/kg), or placebo. Primary endpoint was average change from baseline at weeks 4 and 6 in MAS ankle score. Secondary endpoints included the Modified Tardieu Scale (MTS) and Global Attainment Scale (GAS). RESULTS: 381 participants were randomized. MAS scores averaged at weeks 4 and 6 were significantly reduced with both onabotulinumtoxinA doses (8U/kg:-1.06, p=0.010; 4U/kg:-1.01, p=0.033) versus placebo (-0.8). Significant improvements in average dynamic component of spasticity, measured by MTS, and in function, measured by GAS, were observed at several time points with both onabotulinumtoxinA doses versus placebo. Most adverse events were mild or moderate. CONCLUSIONS: OnabotulinumtoxinA was well tolerated and effective in reducing lower limb spasticity and improving functional outcomes versus placebo in children.

Original languageEnglish
Pages (from-to)33-46
Number of pages14
JournalNeuroRehabilitation
Volume50
Issue number1
DOIs
StatePublished - 2022

Keywords

  • Children
  • lower limb
  • onabotulinumtoxinA
  • randomized clinical trial
  • spasticity

Fingerprint

Dive into the research topics of 'Efficacy and safety of onabotulinumtoxinA with standardized physiotherapy for the treatment of pediatric lower limb spasticity: A randomized, placebo-controlled, phase III clinical trial'. Together they form a unique fingerprint.

Cite this